Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%
Market cap
$31.3B
P/E
39.5×
Fwd P/E
39.6×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more quarters

1,249.03 1,097.03 1,167.18 1,290.95
Revenue Growth
149.35% 84.95% 96.43% 66.86%
Gross Profit
1,048.87 829.31 956.05 992.50
Operating Income
367.98 131.72 268.64 231.44
EBT
238.97 127.86 221.65 177.81
Income after Tax
251.08 153.14 205.99 164.49
Net Income Common
251.08 153.14 205.99 164.49
EPS (Diluted)
1.84 1.20 1.51 1.21
Shares (Diluted, Weighted)
137.35 134.68 138.23 138.28
Gross Margin
83.98% 75.60% 81.91% 76.88%
EBIT Margin
29.46% 12.01% 23.02% 17.93%
Net Profit Margin
20.10% 13.96% 17.65% 12.74%
EBITDA
381.79 145.22 282.19 245.34
EBIT
367.98 131.72 268.64 231.44

Show all line items

In millions of $ except per-share values · columns are period end dates